Illumina (NASDAQ:ILMN) Beats Q4 Sales Targets
Genomics company Illumina (NASDAQ:ILMN) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales were flat year on year at $1.1 billion. On the other hand, the company’s full-year revenue guidance of $4.34 billion at the midpoint came in 1.2% below analysts’ estimates. Its non-GAAP profit of $0.86 per share was 6.9% below analysts’ consensus estimates.